Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics

Treating Remethylation Disorders: Boosting the Recycling Path

At a Glance

Homocystinuria without methylmalonic aciduria is treated by supporting homocysteine recycling with individualized betaine, hydroxocobalamin injections, and the right folate form. Methionine restriction is usually avoided, and lifelong lab monitoring helps keep treatment safe.

Treating isolated remethylation disorders (like severe MTHFR deficiency, cblE, and cblG) requires a completely different approach than treating CBS deficiency. In these conditions, the body is struggling to “recycle” homocysteine back into methionine. Because of this, your treatment is focused on providing the missing building blocks and using alternative pathways to keep the recycling process moving [1][2].

Usually No Methionine Restriction; Individualized Management

One of the most important differences in treating these disorders is the diet. Unlike people with CBS deficiency, who must strictly limit protein, people with remethylation disorders generally should not restrict methionine [1].

  • In your case, methionine levels are usually already low or at the low end of normal [3].
  • Methionine is essential for growth, brain health, and a process called methylation, which acts like a “volume knob” for your genes [4][5].
  • Restricting protein could make your methionine levels drop dangerously low. In fact, some patients may even need specialist-directed methionine supplementation if their levels remain too low despite other treatments. However, betaine can raise methionine, so your dietitian will track your labs serially to individualize your plan [1][6].

The Role of Betaine (Cystadane)

For MTHFR deficiency, betaine is the first-line treatment [2].

  • How it works: Betaine bypasses the impaired MTHFR enzyme and uses a different pathway (mostly in the liver) to turn homocysteine back into methionine [5][7].
  • Dosing: Doses are highly individualized based on age, weight, and your biochemical response. There is no standard dose for everyone. Your doctor will determine the exact amount you need to reach your target levels, and you must never alter this dose independently [8][1].

Vitamin Injections for cblE and cblG

If you have cblE or cblG, the primary treatment is high-dose hydroxocobalamin (Vitamin B12) [1][2].

  • Method: This is typically given as a parenteral injection (into the muscle or under the skin), often daily or several times a week [9]. Injections are used because they provide much higher levels of B12 directly to the cells than oral vitamins can achieve [9].
  • Purpose: These high doses help “jumpstart” the enzyme that recycles homocysteine [6]. Many people with these conditions also take betaine alongside their injections to further lower homocysteine and boost methionine [6][10].

Folate and Other Supplements

Most treatment plans include some form of folate to support the recycling pathway, but the type must be carefully selected by your metabolic team.

  • Folinic Acid or 5-MTHF: In severe MTHFR deficiency, standard folic acid may not be enough. Your doctor may prescribe folinic acid or 5-methyltetrahydrofolate (mefolinate), which is the specific form of folate the body is struggling to make [5][11]. You should never substitute one form of folate for another without medical direction.
  • Monitoring: Your team will monitor your Complete Blood Count (CBC) to check for anemia (low red blood cells) and other blood-related issues that can occur in these disorders [6][10].

The Importance of Early Treatment

The goal of all these treatments is to keep your homocysteine and methionine levels as close to the normal range as possible [1]. Starting treatment early—ideally before any symptoms appear—can substantially reduce the risk of long-term complications [12][13]. While treatment can often stabilize or improve neurological symptoms like coordination or mood issues, some symptoms may be permanent, which is why consistent, lifelong management is so important [11][14].

Common questions in this guide

What is the main treatment for severe MTHFR deficiency?
Betaine, also known as Cystadane, is generally the first-line treatment for severe MTHFR deficiency. It uses an alternate pathway to help convert homocysteine back into methionine, but the dose must be set and adjusted by the metabolic team based on laboratory results.
Should I restrict protein or methionine with a remethylation disorder?
Usually no: people with isolated remethylation disorders often have low or low-normal methionine, so routine methionine restriction can make levels too low. Do not change protein intake or start methionine supplements without your metabolic team, because betaine and other treatments can change methionine levels.
How are cblE and cblG treated?
cblE and cblG are usually treated with high-dose hydroxocobalamin, a form of vitamin B12, given by injection into a muscle or under the skin. Injections are often given daily or several times a week, and betaine may be added to help lower homocysteine and raise methionine.
Which folate supplement is used for remethylation disorders?
The appropriate form depends on the specific enzyme defect. In severe MTHFR deficiency, a clinician may prescribe folinic acid or 5-methyltetrahydrofolate, also called 5-MTHF or mefolinate, because standard folic acid may not be enough; do not switch products without medical guidance.
What tests are used to monitor treatment?
The care team follows homocysteine and methionine levels to judge whether treatment is working and to adjust the plan. A complete blood count may also be checked for anemia and other blood-related problems, while symptoms and treatment adherence are reviewed over time.
Can early treatment prevent lasting symptoms?
Starting treatment before symptoms appear can substantially reduce the risk of long-term complications. Treatment may stabilize or improve neurological symptoms such as coordination or mood changes, but some effects can be permanent, so consistent lifelong management is important.

Get notified when new evidence is published on Homocystinuria without methylmalonic aciduria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders.

    Olivieri G, Bordugo A, Burnyte B, et al.

    Journal of inherited metabolic disease 2026; (49(4)):e70177 doi:10.1002/jimd.70177.

    PMID: 42231716
  2. 2

    Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency.

    Huemer M, Diodato D, Schwahn B, et al.

    Journal of inherited metabolic disease 2017; (40(1)):21-48 doi:10.1007/s10545-016-9991-4.

    PMID: 27905001
  3. 3

    Pilot Study on Neonatal Screening for Methylmalonic Acidemia Caused by Defects in the Adenosylcobalamin Synthesis Pathway and Homocystinuria Caused by Defects in Homocysteine Remethylation.

    Kagawa R, Tajima G, Maeda T, et al.

    International journal of neonatal screening 2021; (7(3)) doi:10.3390/ijns7030039.

    PMID: 34287232
  4. 4

    Vitamin B-12 and liver activity and expression of methionine synthase are decreased in fetuses with neural tube defects.

    Fofou-Caillierez MB, Guéant-Rodriguez RM, Alberto JM, et al.

    The American journal of clinical nutrition 2019; (109(3)):674-683 doi:10.1093/ajcn/nqy340.

    PMID: 30848279
  5. 5

    Treatment with Mefolinate (5-Methyltetrahydrofolate), but Not Folic Acid or Folinic Acid, Leads to Measurable 5-Methyltetrahydrofolate in Cerebrospinal Fluid in Methylenetetrahydrofolate Reductase Deficiency.

    Knowles L, Morris AA, Walter JH

    JIMD reports 2016; (29()):103-107 doi:10.1007/8904_2016_529.

    PMID: 26898294
  6. 6

    Late-onset refractory hemolytic anemia in siblings treated for methionine synthase reductase deficiency: A rare complication possibly prevented by hydroxocobalamin dose escalation?

    Nguyen A, Deshayes S, Nowoczyn M, et al.

    JIMD reports 2024; (65(3)):163-170 doi:10.1002/jmd2.12422.

    PMID: 38736634
  7. 7

    Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial.

    Imbard A, Toumazi A, Magréault S, et al.

    Orphanet journal of rare diseases 2022; (17(1)):417 doi:10.1186/s13023-022-02567-4.

    PMID: 36376887
  8. 8

    Betaine anhydrous in homocystinuria: results from the RoCH registry.

    Valayannopoulos V, Schiff M, Guffon N, et al.

    Orphanet journal of rare diseases 2019; (14(1)):66 doi:10.1186/s13023-019-1036-2.

    PMID: 30871635
  9. 9

    Subcutaneous vitamin B12 administration using a portable infusion pump in cobalamin-related remethylation disorders: a gentle and easy to use alternative to intramuscular injections.

    Lotz-Havla AS, Weiß KJ, Schiergens KA, et al.

    Orphanet journal of rare diseases 2021; (16(1)):215 doi:10.1186/s13023-021-01847-9.

    PMID: 33980297
  10. 10

    Methionine synthase reductase deficiency (CblE): A report of two patients and a novel mutation.

    Ruiz-Mercado M, Vargas MT, de Soto IP, et al.

    Hematology (Amsterdam, Netherlands) 2016; (21(3)):193-7 doi:10.1179/1607845415Y.0000000017.

    PMID: 25978498
  11. 11

    [Analysis of 9 patients with adolescence-onset methylenetetrahydrofolate reductase deficiency].

    Zhang HT, Ma X, Jin Y, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2024; (62(4)):357-362 doi:10.3760/cma.j.cn112140-20230919-00200.

    PMID: 38527507
  12. 12

    Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry.

    Huemer M, Diodato D, Martinelli D, et al.

    Journal of inherited metabolic disease 2019; (42(2)):333-352 doi:10.1002/jimd.12041.

    PMID: 30773687
  13. 13

    Influence of early identification and therapy on long-term outcomes in early-onset MTHFR deficiency.

    Yverneau M, Leroux S, Imbard A, et al.

    Journal of inherited metabolic disease 2022; (45(4)):848-861 doi:10.1002/jimd.12504.

    PMID: 35460084
  14. 14

    Clinical and molecular characterization of adult patients with late-onset MTHFR deficiency.

    Marelli C, Lavigne C, Stepien KM, et al.

    Journal of inherited metabolic disease 2021; (44(3)):777-786 doi:10.1002/jimd.12323.

    PMID: 33089527

This page is for informational purposes only and does not constitute medical advice. Your metabolic team must individualize betaine, hydroxocobalamin, folate, diet, and laboratory monitoring for your specific condition.

Guide contents Homocystinuria without methylmalonic aciduria
Research & Literature
04 Treating CBS Deficiency 06 Staying Healthy